Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Advancing Cancer Vaccines
A Drug Class Almost Ready to Take Off
- The cadre of speakers extolling the virtues of therapeutic cancer vaccines at the recent “World Vaccine Congress” in Lyon, France, included Vincent Brichard, M.D., Ph.D., vp, cancer immunotherapeutics, GlaxoSmithKline Biologicals (www.gsk-bio.com). “Many would say that therapeutic cancer vaccines have experienced 20 years of failure, but I would say it ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.